• Top > 
  • Industry > 
  • (TAKEDA PHARMA) Fasiglifam (TAK-875), a Novel GPR40 Agonist Reduces HbA1c in a 24-Week Clinical Study - Phase III Study Results Presented at the 56th Annual Meeting of the Japan Diabetes Society

Details

2013/05/16 17:06

(TAKEDA PHARMA) Fasiglifam (TAK-875), a Novel GPR40 Agonist Reduces HbA1c in a 24-Week Clinical Study - Phase III Study Results Presented at the 56th Annual Meeting of the Japan Diabetes Society

Osaka, Japan, May 16, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today the results of a Phase III clinical trial (CCT-003) of fasiglifam (Development code:TAK-875) for the treatment of type 2 diabetes presented at the 56th Annual Meeting of the Japan Diabetes Society, being held from the 16th through 18th of May 2013 in Kumamoto, Japan. 【Read more...Original Site】

Source : Takeda Pharmaceutical Company Limited

The latest category